Last reviewed · How we verify
Universidade Federal de Sergipe — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Piroxicam-Beta-Cyclodextrin | Piroxicam-Beta-Cyclodextrin | phase 3 | Nonsteroidal anti-inflammatory drug (NSAID) | Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) | Rheumatology / Pain Management |
Therapeutic area mix
- Rheumatology / Pain Management · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Actavis Inc. · 1 shared drug class
- Amneal Pharmaceuticals, LLC · 1 shared drug class
- Amzell · 1 shared drug class
- Assaf-Harofeh Medical Center · 1 shared drug class
- Azienda USL Reggio Emilia - IRCCS · 1 shared drug class
- Bausch & Lomb Incorporated · 1 shared drug class
- Bayer · 1 shared drug class
- Abbott · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Universidade Federal de Sergipe:
- Universidade Federal de Sergipe pipeline updates — RSS
- Universidade Federal de Sergipe pipeline updates — Atom
- Universidade Federal de Sergipe pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Universidade Federal de Sergipe — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/universidade-federal-de-sergipe. Accessed 2026-05-16.